DLDongni Lin

Dongni Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dongni Lin has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Jiaoyang Liao

    Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China

    2 shared publications
  • Ling Xiao

    Yoltech Therapeutics, Shanghai, China

    2 shared publications
  • Mei Long

    Department of Liver Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Michael Ott

    Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany

    2 shared publications
  • Ping Wan

    Department of Liver Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Qiang Xia

    Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications

Latest Publications

  • Author Correction: In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial

    by Ping Wan, Siyuan Tang, Dongni Lin, Yuming Lu, Mei Long, Ling Xiao, Yanhong Jiang, Jiaoyang Liao, Xiaoying Ma, Ying Liu, et al.

  • Top Cited Papers

    In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial

    by Ping Wan, Siyuan Tang, Dongni Lin, Yuming Lu, Mei Long, Ling Xiao, Yanhong Jiang, Jiaoyang Liao, Xiaoying Ma, Ying Liu, et al.

    Heterozygous familial hypercholesterolemia is a common genetic disorder characterized by lifelong elevation of serum low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. YOLT-101 is an investigational in vivo gene therapy that uses adenine base-editing technology, delivered via GalNAc-modified lipid nanoparticles to inactivate PCSK9 and achieve sustained LDL-C reduction. Here we report interim results from an ongoing clinical trial evaluating primary (safety and tolerability) and secondary (lowering of PCSK9 and LDL-C levels) outcomes of a single intravenous dose of YOLT-101 in adults with heterozygous familial hypercholesterolemia and uncontrolled LDL-C. Six participants (three men and three women) received escalating doses of YOLT-101 (0.2, 0.4 or 0.6 mg kg-1). No grade ≥3 adverse events occurred. Transient and self-limited infusion-related reactions and elevations in liver enzymes were the most common adverse events. A single infusion of YOLT-101 induced dose-dependent and durable reductions in circulating PCSK9 and LDL-C, with sustained reductions of 74.4% and 52.3%, respectively, at 24 weeks in the 0.6 mg kg-1 cohort (n = 3), demonstrating promise for future clinical development. ClinicalTrials.gov registration: NCT06458010 .